Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$462.88 USD

462.88
710,709

-0.27 (-0.06%)

Updated Sep 27, 2024 04:00 PM ET

After-Market: $462.85 -0.03 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Can Vertex (VRTX) Withstand the Coronavirus Impact on Q1 Earnings?

On Vertex's (VRTX) first-quarter earnings call, investor focus will be on the sales uptake of its newly-launched CF drug, Trikafta.

Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

Vertex (VRTX) Hits Fresh High: Is There Still Room to Run?

Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth

Vertex (VRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sheraz Mian headshot

Earnings Scorecard and Top Stock Reports for Alphabet, Gilead & Starbucks

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Gilead Sciences (GILD) and Starbucks (SBUX).

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $246.61 in the latest trading session, marking a -1.22% move from the prior day.

The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer

The Zacks Analyst Blog Highlights: Amazon, Medtronic, Vertex Pharmaceuticals, Intuit and Bayer

Vertex Pharmaceuticals (VRTX) Dips More Than Broader Markets: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $238.31, moving -1.59% from the previous trading session.

Sheraz Mian headshot

Top Research Reports for Amazon, Medtronic & Vertex

Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Medtronic (MDT) and Vertex Pharmaceuticals (VRTX).

Indrajit Bandyopadhyay headshot

3 Drugmakers Still Worth Betting on Amid Coronavirus Woes

Here we provide three stocks from the drug and biotech sector which can offer protection to an investor's portfolio amid stock market turmoil due to coronavirus crisis.

Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

Vertex to Halt Enrollment Due to Coronavirus, Keeps Sales View

Vertex (VRTX) announces plan to halt enrollment and delay study initiation amid coronavirus pandemic. However, it does not expect any supply chain disruption and maintains its business outlook for 2020.

Vertex Pharmaceuticals (VRTX) Gains As Market Dips: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $213.52, moving +1.46% from the previous trading session.

Zacks.com featured highlights include: Fabrinet, Lumentum, Daqo New Energy and Vertex Pharmaceuticals

Zacks.com featured highlights include: Fabrinet, Lumentum, Daqo New Energy and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Co-Diagnostics, Moderna and Vertex Pharmaceuticals

Tirthankar Chakraborty headshot

4 Top Biotech Stocks to Buy in the Time of Coronavirus

We have picked biotech companies that are widely expected to develop a vaccine for the coronavirus and fight off the worst stock market carnage since the 2008 financial crisis.

Sumit Singh headshot

Pick These 4 Stocks With Impressive Interest Coverage Ratio

Debt, which is crucial to financing operations for the majority of companies, comes at a cost called interest. Interest expense has a direct bearing on the profitability of a company.

Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates

Geron (GERN) reports encouraging fourth-quarter 2019 results. Operating expenses increase on a year-over-year basis.

BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates

BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.

Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

Sanghamitra Saha headshot

5 Top Stocks With Great Earnings Beat Potential

These top-ranked stocks are likely to beat on the bottom line in their next release.

Why Is Vertex (VRTX) Down 2.7% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Perrigo (PRGO) Misses Q4 Earnings Estimates, Tops Revenues

Perrigo (PRGO) reports mixed fourth-quarter 2019 results. The addition of products following Ranir acquisition boosts sales in the quarter. Stock declines.

Sarepta (SRPT) Q4 Loss Widens Y/Y, Revenues Miss Estimates

Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.

BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus

BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.